UCB S.A.'s hopes of launching Bimzelx in the US this year have been scuppered again by regulators across the Atlantic who have rejected the potential blockbuster for inflammatory diseases, citing facility inspection issues.
Bimzelx (bimekizumab) comfortably secured approval for psoriasis in the EU and the UK in August last year but the regulatory...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?